Evaluating Clinical and Sociodemographic Risk for Symptom Burden Associated Interference With Daily Functioning in the Primary Brain Tumor Patient Population.

Introduction: Symptom burden associated with interference in daily functioning is worse in those with progression or higher-grade glial tumors. This exploratory study aims to identify factors associated with its severity in a diverse cross-sectional cohort of 566 brain tumor patients enrolled in a natural history study (NCT03251989, PI: T.S.

ICAM-1 and IL-10 are associated with cognitive dysfunction using the MoCA test in glioma: Findings from the NCI Neuro-Oncology Branch Natural History Study.

Background: Cognitive dysfunction is common among patients with malignant glioma, yet the underlying mechanisms of this dysfunction remain unclear. Protein markers of neurodegeneration, inflammation, and vascular damage have been associated with central nervous system pathology and with cognitive changes in neurological diseases, but their clinical utility in gliomas is unknown. This study examined the relationships between cognitive dysfunction, tumor isocitrate dehydrogenase (IDH) mutation status in gliomas, and a panel of blood-based protein biomarkers.

MRI Relaxometry for Glioblastoma Response Assessment During Radiation Therapy on a 0.35 T MRI Linear Accelerator.

Background And Purpose: The integration of MRI and linear accelerator (MRI-Linac) enables daily imaging during radiation therapy (RT). This study implements MRI-Linac relaxometry to evaluate quantitative imaging changes in glioblastoma patients during RT and identify associations with disease progression and survival outcomes.

Materials And Methods: Thirty-eight glioblastoma patients were treated on a 0.

Social Determinants of Health Predict Sleep-Wake Disturbances Among Patients Living With Primary Brain Tumors: A Cross-Sectional Analysis.

Introduction: Sleep disturbance (SD) and sleep-related impairment (SRI) significantly impact the lives of primary brain tumor (PBT) patients. We aimed to describe the prevalence of SD and SRI in this population, determine the reliability of the PROMIS-SD and PROMIS-SRI instruments, and identify predictive factors to support the development of targeted interventions for at-risk individuals.

Methods: This cross-sectional study evaluated SD and SRI in PBT patients enrolled in a Natural History Study who completed 1-year follow-up questionnaires (N = 229).

The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations.

Background: This study explored differences in patient-reported outcomes (PROs) for patients with central nervous system (CNS) tumors during COVID, compared to pre-pandemic assessments, in light of impacted access to in-person care.

Methods: Patient-reported outcomes (PROMIS-Anxiety and Depression Short-Forms, EQ-5D-3L, MDASI-BT/Spine, NeuroQoL-Perceived Cognitive Functioning) were collected from 149 participants on the Neuro-Oncology Branch Natural History Study seen during the first year of COVID between March 2020 and February 2021, which were compared to assessments collected pre-COVID. Paired sample -tests and proportion tests (-tests) were used to compare PROs with effect sizes reported using Hedges and Cohen's .